# Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

> **NCT02867592** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 109 (actual)

## Conditions studied

- Adrenal Cortical Carcinoma
- Alveolar Soft Part Sarcoma
- Central Nervous System Neoplasm
- Childhood Clear Cell Sarcoma of Soft Tissue
- Clear Cell Sarcoma of Soft Tissue
- Ewing Sarcoma
- Hepatoblastoma
- Hepatocellular Carcinoma
- Osteosarcoma
- Recurrent Adrenal Cortical Carcinoma
- Recurrent Alveolar Soft Part Sarcoma
- Recurrent Clear Cell Sarcoma of Soft Tissue
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Hepatocellular Carcinoma
- Recurrent Kidney Wilms Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Osteosarcoma
- Recurrent Primary Malignant Central Nervous System Neoplasm
- Recurrent Renal Cell Carcinoma
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent Thyroid Gland Medullary Carcinoma
- Refractory Adrenal Cortical Carcinoma
- Refractory Alveolar Soft Part Sarcoma
- Refractory Clear Cell Sarcoma of Soft Tissue
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Hepatocellular Carcinoma
- Refractory Malignant Solid Neoplasm
- Refractory Osteosarcoma
- Refractory Primary Central Nervous System Neoplasm
- Refractory Primary Malignant Central Nervous System Neoplasm
- Refractory Renal Cell Carcinoma
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
- Refractory Thyroid Gland Medullary Carcinoma
- Refractory Wilms Tumor
- Renal Cell Carcinoma
- Rhabdomyosarcoma
- Soft Tissue Sarcoma
- Solid Neoplasm
- Thyroid Gland Medullary Carcinoma
- Wilms Tumor

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Cabozantinib S-malate
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02867592
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-18
- **Primary completion:** 2021-06-30
- **Final completion:** 2026-06-27
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867592, "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02867592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*